Copyright
©The Author(s) 2021.
World J Transplant. Jul 18, 2021; 11(7): 303-319
Published online Jul 18, 2021. doi: 10.5500/wjt.v11.i7.303
Published online Jul 18, 2021. doi: 10.5500/wjt.v11.i7.303
Figure 1 Outline of search methodology, PRISMA 2009 flow diagram.
Figure 2 Pooled risk ratio of focal segmental glomerulosclerosis recurrence between the group that received rituximab (with or without plasmapheresis) and the standard treatment group.
Figure 3 Pooled risk ratio of focal segmental glomerulosclerosis recurrence between patients who did and did not receive plasmapheresis.
Figure 4 Funnel plot evaluating publication bias regarding the effects of rituximab on focal segmental glomerulosclerosis recurrence.
Figure 5 Funnel plot evaluating publication bias regarding the effects of plasmapheresis on focal segmental glomerulosclerosis recurrence.
- Citation: Boonpheng B, Hansrivijit P, Thongprayoon C, Mao SA, Vaitla PK, Bathini T, Choudhury A, Kaewput W, Mao MA, Cheungpasitporn W. Rituximab or plasmapheresis for prevention of recurrent focal segmental glomerulosclerosis after kidney transplantation: A systematic review and meta-analysis. World J Transplant 2021; 11(7): 303-319
- URL: https://www.wjgnet.com/2220-3230/full/v11/i7/303.htm
- DOI: https://dx.doi.org/10.5500/wjt.v11.i7.303